SkinBioTherapeutics PLC

Research SkinBioTherapeutics PLC (SBTX) on Bullrun: market cap GBX 2.94B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSBTX
• ExchangeLSE
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyGBX
• Market capGBX 2.94B
• Financial periodFY2025
• RevenueGBP 4.64M
• Revenue growth283.7%
• Net income-GBP 696.25K
• Free cash flow-GBP 1.39M
• Gross margin61.6%

Valuation Snapshot

latest market cap is GBX 2.94B.

About SkinBioTherapeutics PLC

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development.

Frequently asked questions

What is SkinBioTherapeutics PLC's market cap?

SkinBioTherapeutics PLC's market capitalization is GBX 2.94B.

What does SkinBioTherapeutics PLC do?

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally.